Download PDF
Semin Vasc Med 2003; 03(2): 185-192
DOI: 10.1055/s-2003-40676
Copyright © 2003 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Tissue Factor in Acute Coronary Syndromes

Ilka Ott
  • Deutsches Herzzentrum und 1. Medizinische Klinik der Technischen Universität Munich, Germany
Further Information

Publication History

Publication Date:
18 July 2003 (online)

    Permissions and Reprints

ABSTRACT

Thrombosis at the site of atherosclerotic plaque disruption is the principal cause of acute coronary syndromes. The severity of the clinical consequences is determined by the extent and the progression of the thrombus that are caused by local and systemic factors. In atherosclerotic lesions mediators induce tissue factor (TF) in macrophages, smooth muscle cells, and endothelial cells. Procoagulant microparticles in the lipid core further enhance the thrombogenicity of the plaque. In addition, in acute coronary syndromes circulating monocytes and microparticles express TF and, thereby, contribute to systemic procoagulant activity. As a regulatory mechanism surface-bound, endogenous tissue factor pathway inhibitor-1 (TFPI) inhibits TF activity by translocation of the quaternary complex TF-FVIIa-FXa-TFPI into glycosphingolipid-rich microdomains more efficiently than exogenously added TFPI. This inhibition occurs not only in endothelial cells but also on circulating monocytes and presumably microparticles. Because therapeutic thrombolysis in acute myocardial infarction degrades TFPI, a prothrombotic state due to unopposed TF activity may occur. Several studies have demonstrated a contribution of local and bloodborne TF to thrombus formation; a direct relationship with the clinical outcome, however, awaits further studies. This article discusses the current understanding of the role of TF and its regulation by TFPI in acute coronary syndromes.

KEYWORDS

Tissue factor - acute coronary syndrome - coagulation - thrombolysis

REFERENCES

  • 1 Zhou J, Chew M, Ravn H B. Plaque pathology and coronary thrombosis in the pathogenesis of acute coronary syndromes.  Scand J Clin Lab Invest Suppl . 1999;  230 3-11
    PubMedGoogle Scholar
  • 2 Tremoli E, Camera M, Toschi V. Tissue factor in atherosclerosis.  Atherosclerosis . 1999;  144 273-283
    CrossrefPubMedGoogle Scholar
  • 3 Moss A J, Goldstein R E, Marder V J. Thrombogenic factors and recurrent coronary events.  Circulation . 1999;  99 2517-2522
    CrossrefPubMedGoogle Scholar
  • 4 Ruf W. The interaction of activated factor VII with tissue factor: insight into the mechanism of cofactor-mediated activation of activated factor VII.  Blood Coagul Fibrinolysis . 1998;  9 S73-S78
    PubMedGoogle Scholar
  • 5 Wilcox J N, Smith K M, Schwartz S M. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque.  Proc Natl Acad Sci USA . 1989;  86 2839-2843
    PubMedGoogle Scholar
  • 6 McVey J H. Tissue factor pathway.  Baillieres Best Pract Res Clin Haematol . 1999;  12 361-372
    CrossrefPubMedGoogle Scholar
  • 7 Hatakeyama K, Asada Y, Marutsuka K. Localization and activity of tissue factor in human aortic atherosclerotic lesions.  Atherosclerosis . 1997;  133 213-219
    CrossrefPubMedGoogle Scholar
  • 8 Thiruvikraman S V, Guha A, Roboz J. In situ localization of tissue factor in human atherosclerotic plaques by binding of digoxigenin-labeled factors VIIa and X.  Lab Invest . 1996;  75 451-461
    PubMedGoogle Scholar
  • 9 Marmur J D, Thiruvikraman S V, Fyfe B S. Identification of active tissue factor in human coronary atheroma.  Circulation . 1996;  94 1226-1232
    CrossrefPubMedGoogle Scholar
  • 10 Mallat Z, Hugel B, Ohan J. Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques: a role for apoptosis in plaque thrombogenicity.  Circulation . 1999;  99 348-353
    CrossrefPubMedGoogle Scholar
  • 11 Schecter A D, Spirn B, Rossikhina M. Release of active tissue factor by human arterial smooth muscle cells.  Circ Res . 2000;  87 126-132
    CrossrefPubMedGoogle Scholar
  • 12 Mallat Z, Tedgui A. Apoptosis in the vasculature: mechanisms and functional importance.  Br J Pharmacol . 2000;  130 947-962
    CrossrefPubMedGoogle Scholar
  • 13 Zhang J, Reedy M C, Hannun Y A. Inhibition of caspases inhibits the release of apoptotic bodies: bcl-2 inhibits the initiation of formation of apoptotic bodies in chemotherapeutic agent-induced apoptosis.  J Cell Biol . 1999;  145 99-108
    CrossrefPubMedGoogle Scholar
  • 14 Leatham E W, Bath P M, Tooze J A. Increased monocyte tissue factor expression in coronary disease.  Br Heart J . 1995;  73 10-13
    PubMedGoogle Scholar
  • 15 Ott I, Andrassy M, Zieglgansberger D. Regulation of monocyte procoagulant activity in acute myocardial infarction: role of tissue factor and tissue factor pathway inhibitor-1.  Blood . 2001;  97 3721-3726
    CrossrefPubMedGoogle Scholar
  • 16 Kappelmayer J, Berecki D, Misz M. Monocytes express tissue factor in young patients with cerebral ischemia.  Cerebrovasc Dis . 1998;  8 235-239
    PubMedGoogle Scholar
  • 17 Osterud B, Bjorklid E. The tissue factor pathway in disseminated intravascular coagulation.  Semin Thromb Hemost . 2001;  27 605-617
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Moons A H, Levi M, Peters R J. Tissue factor and coronary artery disease.  Cardiovasc Res . 2002;  53 313-325
    CrossrefPubMedGoogle Scholar
  • 19 Corseaux D, Le Tourneau T, Six I. Enhanced monocyte tissue factor response after experimental balloon angioplasty in hypercholesterolemic rabbit: inhibition with dietary L-arginine.  Circulation . 1998;  98 1776-1782
    PubMedGoogle Scholar
  • 20 Siddiqui F A, Desai H, Amirkhosravi A. The presence and release of tissue factor from human platelets.  Platelets . 2002;  13 247-253
    CrossrefPubMedGoogle Scholar
  • 21 Giesen P L, Rauch U, Bohrmann B. Blood-borne tissue factor: another view of thrombosis.  Proc Natl Acad Sci USA . 1999;  96 2311-2315
    Google Scholar
  • 22 Zillmann A, Luther T, Muller I. Platelet-associated tissue factor contributes to the collagen-triggered activation of blood coagulation.  Biochem Biophys Res Commun . 2001;  281 603-609
    PubMedGoogle Scholar
  • 23 Lawson C, Ainsworth M, Yacoub M. Ligation of ICAM-1 on endothelial cells leads to expression of VCAM-1 via a nuclear factor-kappaB-independent mechanism.  J Immunol . 1999;  162 2990-2996
    PubMedGoogle Scholar
  • 24 Broze Jr J G. Tissue factor pathway inhibitor and the revised theory of coagulation.  Annu Rev Med . 1995;  46 103-112
    CrossrefPubMedGoogle Scholar
  • 25 Broze Jr J G. Tissue factor pathway inhibitor.  Thromb Haemost . 1995;  74 90-93
    PubMedGoogle Scholar
  • 26 Ohkura N, Enjyoji K, Kamikubo Y. A novel degradation pathway of tissue factor pathway inhibitor: incorporation into fibrin clot and degradation by thrombin.  Blood . 1997;  90 1883-1892
    PubMedGoogle Scholar
  • 27 Li A, Wun T C. Proteolysis of tissue factor pathway inhibitor (TFPI) by plasmin: effect on TFPI activity.  Thromb Haemost . 1998;  80 423-427
    PubMedGoogle Scholar
  • 28 Salemink I, Franssen J, Willems G M. Factor Xa cleavage of tissue factor pathway inhibitor is associated with loss of anticoagulant activity.  Thromb Haemost . 1998;  80 273-280
    PubMedGoogle Scholar
  • 29 Higuchi D A, Wun T C, Likert K M. The effect of leukocyte elastase on tissue factor pathway inhibitor.  Blood . 1992;  79 1712-1719
    PubMedGoogle Scholar
  • 30 Belaaouaj A, Li A, Wun T. Matrix metalloproteinases cleave tissue factor pathway inhibitor: effects on coagulation.  J Biol Chem . 2000;  275 27123-27128
    PubMedGoogle Scholar
  • 31 Kato H. Tissue factor pathway inhibitor; its structure, function and clinical significance.  Pol J Pharmacol . 1996;  48 67-72
    PubMedGoogle Scholar
  • 32 Lupu C, Lupu F, Dennehy U. Thrombin induces the redistribution and acute release of tissue factor pathway inhibitor from specific granules within human endothelial cells in culture.  Arterioscler Thromb Vasc Biol . 1995;  15 2055-2062
    CrossrefPubMedGoogle Scholar
  • 33 Hansen J B, Svensson B, Olsen R. Heparin induces synthesis and secretion of tissue factor pathway inhibitor from endothelial cells in vitro.  Thromb Haemost . 2000;  83 937-943
    Google Scholar
  • 34 Lupu C, Poulsen E, Roquefeuil S. Cellular effects of heparin on the production and release of tissue factor pathway inhibitor in human endothelial cells in culture.  Arterioscler Thromb Vasc Biol . 1999;  19 2251-2262
    Google Scholar
  • 35 Kato H. Regulation of functions of vascular wall cells by tissue factor pathway inhibitor: basic and clinical aspects.  Arterioscler Thromb Vasc Biol . 2002;  22 539-548
    CrossrefPubMedGoogle Scholar
  • 36 Sevinsky J R, Rao L V, Ruf W. Ligand-induced protease receptor translocation into caveolae: a mechanism for regulating cell surface proteolysis of the tissue factor-dependent coagulation pathway.  J Cell Biol . 1996;  133 293-304
    Google Scholar
  • 37 Lupu C, Goodwin C A, Westmuckett A D. Tissue factor pathway inhibitor in endothelial cells colocalizes with glycolipid microdomains/caveolae. Regulatory mechanism(s) of the anticoagulant properties of the endothelium.  Arterioscler Thromb Vasc Biol . 1997;  17 2964-2974
    CrossrefPubMedGoogle Scholar
  • 38 Ott I, Vukovitsch R, Ruf W. Glycosyl phosphatidylinositol-anchored tissue factor pathway inhibitor-1 gene transfer inhibits tissue factor activity in ECV304 cells.  Ann Hematol . 2002;  81 (suppl 1) A62
    PubMedGoogle Scholar
  • 39 Kojima T, Katsumi A, Yamazaki T. Human ryudocan from endothelium-like cells binds basic fibroblast growth factor, midkine, and tissue factor pathway inhibitor.  J Biol Chem . 1996;  271 5914-5920
    CrossrefPubMedGoogle Scholar
  • 40 Mast A E, Higuchi D A, Huang Z F. Glypican-3 is a binding protein on the HepG2 cell surface for tissue factor pathway inhibitor.  Biochem J . 1997;  327 577-583
    PubMedGoogle Scholar
  • 41 Ott I, Miyagi Y, Miyazaki K. Reversible regulation of tissue factor-induced coagulation by glycosyl phosphatidylinositol-anchored tissue factor pathway inhibitor.  Arterioscler Thromb Vasc Biol . 2000;  20 874-882
    CrossrefPubMedGoogle Scholar
  • 42 Lupu C, Poulsen E, Roquefeuil S. Cellular effects of heparin on the production and release of tissue factor pathway inhibitor in human endothelial cells in culture.  Arterioscler Thromb Vasc Biol . 1999;  19 2251-2262
    Google Scholar
  • 43 Williamson T G, Mok S S, Henry A. Secreted glypican binds to the amyloid precursor protein of Alzheimer's disease (APP) and inhibits APP-induced neurite outgrowth.  J Biol Chem . 1996;  271 31215-31221
    CrossrefPubMedGoogle Scholar
  • 44 Warshawsky I, Broze Jr J G, Schwartz A L. The low density lipoprotein receptor-related protein mediates the cellular degradation of tissue factor pathway inhibitor.  Proc Natl Acad Sci USA . 1994;  91 6664-6668
    PubMedGoogle Scholar
  • 45 Warshawsky I, Herz J, Broze Jr J G. The low density lipoprotein receptor-related protein can function independently from heparan sulfate proteoglycans in tissue factor pathway inhibitor endocytosis.  J Biol Chem . 1996;  271 25873-25879
    CrossrefPubMedGoogle Scholar
  • 46 Ho G, Broze Jr J G, Schwartz A L. Role of heparan sulfate proteoglycans in the uptake and degradation of tissue factor pathway inhibitor-coagulation factor Xa complexes.  J Biol Chem . 1997;  272 16838-16844
    CrossrefPubMedGoogle Scholar
  • 47 Hamik A, Setiadi H, Bu G. Down-regulation of monocyte tissue factor mediated by tissue factor pathway inhibitor and the low density lipoprotein receptor-related protein.  J Biol Chem . 1999;  274 4962-4969
    CrossrefPubMedGoogle Scholar
  • 48 Iakhiaev A, Pendurthi U R, Voigt J. Catabolism of factor VIIa bound to tissue factor in fibroblasts in the presence and absence of tissue factor pathway inhibitor.  J Biol Chem . 1999;  274 36995-37003
    CrossrefPubMedGoogle Scholar
  • 49 Caplice N M, Mueske C S, Kleppe L S. Presence of tissue factor pathway inhibitor in human atherosclerotic plaques is associated with reduced tissue factor activity.  Circulation . 1998;  98 1051-1057
    PubMedGoogle Scholar
  • 50 Crawley J, Lupu F, Westmuckett A D. Expression, localization, and activity of tissue factor pathway inhibitor in normal and atherosclerotic human vessels.  Arterioscler Thromb Vasc Biol . 2000;  20 1362-1373
    CrossrefPubMedGoogle Scholar
  • 51 Kaikita K, Takeya M, Ogawa H. Co-localization of tissue factor and tissue factor pathway inhibitor in coronary atherosclerosis.  J Pathol . 1999;  188 180-188
    PubMedGoogle Scholar
  • 52 Takahashi H, Sato N, Shibata A. Plasma tissue factor pathway inhibitor in disseminated intravascular coagulation: comparison of its behavior with plasma tissue factor.  Thromb Res . 1995;  80 339-348
    CrossrefPubMedGoogle Scholar
  • 53 Falciani M, Gori A M, Fedi S. Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease patients.  Thromb Haemost . 1998;  79 495-499
    PubMedGoogle Scholar
  • 54 Lindahl A K, Odegaard O R, Sandset P M. Coagulation inhibition and activation in pancreatic cancer. Changes during progress of disease.  Cancer . 1992;  70 2067-2072
    PubMedGoogle Scholar
  • 55 Morange P E, Renucci J F, Charles M A. Plasma levels of free and total TFPI, relationship with cardiovascular risk factors and endothelial cell markers.  Thromb Haemost . 2001;  85 999-1003
    PubMedGoogle Scholar
  • 56 Saigo M, Abe S, Ogawa M. Imbalance of plasminogen activator inhibitor-I/tissue plasminogen activator and tissue factor/tissue factor pathway inhibitor in young Japanese men with myocardial infarction.  Thromb Haemost . 2001;  86 1197-1203
    PubMedGoogle Scholar
  • 57 Gando S, Kameue T, Morimoto Y. Tissue factor production not balanced by tissue factor pathway inhibitor in sepsis promotes poor prognosis.  Crit Care Med . 2002;  30 1729-1734
    CrossrefPubMedGoogle Scholar
  • 58 Broze Jr J G. Tissue factor pathway inhibitor and the current concept of blood coagulation.  Blood Coagul Fibrinolysis . 1995;  6 S7-S13
    PubMedGoogle Scholar
  • 59 Novotny W F, Girard T J, Miletich J P. Platelets secrete a coagulation inhibitor functionally and antigenically similar to the lipoprotein associated coagulation inhibitor.  Blood . 1988;  72 2020-2025
    Google Scholar
  • 60 Sandset P M, Warn-Cramer B J, Rao L V. Depletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: evidence supporting a physiologic role for EPI as a natural anticoagulant.  Proc Natl Acad Sci USA . 1991;  88 708-712
    PubMedGoogle Scholar
  • 61 Ragni M, Golino P, Cirillo P. Endogenous tissue factor pathway inhibitor modulates thrombus formation in an in vivo model of rabbit carotid artery stenosis and endothelial injury.  Circulation . 2000;  102 113-117
    CrossrefPubMedGoogle Scholar
  • 62 Abraham E, Reinhart K, Svoboda P. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study.  Crit Care Med . 2001;  29 2081-2089
    CrossrefPubMedGoogle Scholar
  • 63 Ardissino D, Merlini P A, Bauer K A. Thrombogenic potential of human coronary atherosclerotic plaques.  Blood . 2001;  98 2726-2729
    CrossrefPubMedGoogle Scholar
  • 64 Tremoli E, Camera M, Toschi V. Tissue factor in atherosclerosis.  Atherosclerosis . 1999;  144 273-283
    CrossrefPubMedGoogle Scholar
  • 65 Ott I, de Waha R, Koch W. Tissue factor promotor polymorphism is associated with increased risk of myocardial infarction.  Eur Heart J . 2002;  23 227
    PubMedGoogle Scholar
  • 66 Arnaud E, Barbalat V, Nicaud V. Polymorphisms in the 5′ regulatory region of the tissue factor gene and the risk of myocardial infarction and venous thromboembolism: the ECTIM and PATHROS studies. Etude Cas-Temoins de l'Infarctus du Myocarde. Paris Thrombosis case-control Study.  Arterioscler Thromb Vasc Biol . 2000;  20 892-898
    PubMedGoogle Scholar
  • 67 Girelli D, Russo C, Ferraresi P. Polymorphisms in the factor VII gene and the risk of myocardial infarction in patients with coronary artery disease.  N Engl J Med . 2000;  343 774-780
    CrossrefPubMedGoogle Scholar
  • 68 Agraou B, Corseaux D, McFadden E P. Effects of coronary angioplasty on monocyte tissue factor response in patients with stable or unstable angina.  Thromb Res . 1997;  88 237-243
    CrossrefPubMedGoogle Scholar
  • 69 Jude B, Agraou B, McFadden E P. Evidence for time-dependent activation of monocytes in the systemic circulation in unstable angina but not in acute myocardial infarction or in stable angina.  Circulation . 1994;  90 1662-1668
    PubMedGoogle Scholar
  • 70 Ott I, Neumann F J, Kenngott S. Procoagulant inflammatory responses of monocytes after direct balloon angioplasty in acute myocardial infarction.  Am J Cardiol . 1998;  82 938-942
    CrossrefPubMedGoogle Scholar
  • 71 Neumann F J, Ott I, Marx N. Effect of human recombinant interleukin-6 and interleukin-8 on monocyte procoagulant activity.  Arterioscler Thromb Vasc Biol . 1997;  17 3399-3405
    CrossrefPubMedGoogle Scholar
  • 72 Mackman N. Regulation of the tissue factor gene.  FASEB J . 1995;  9 883-889
    PubMedGoogle Scholar
  • 73 Serneri G, Abbate R, Gori A. Transient intermittent lymphocyte activation is responsible for the instability of angina.  Circulation . 1992;  86 790-797
    PubMedGoogle Scholar
  • 74 Lindmark E, Tenno T, Siegbahn A. Role of platelet P-selectin and CD40 ligand in the induction of monocytic tissue factor expression.  Arterioscler Thromb Vasc Biol . 2000;  20 2322-2328
    CrossrefPubMedGoogle Scholar
  • 75 Suefuji H, Ogawa H, Yasue H. Increased plasma tissue factor levels in acute myocardial infarction.  Am Heart J . 1997;  134 253-259
    CrossrefPubMedGoogle Scholar
  • 76 Misumi K, Ogawa H, Yasue H. Comparison of plasma tissue factor levels in unstable and stable angina pectoris.  Am J Cardiol . 1998;  81 22-26
    CrossrefPubMedGoogle Scholar
  • 77 Soejima H, Ogawa H, Yasue H. Heightened tissue factor associated with tissue factor pathway inhibitor and prognosis in patients with unstable angina.  Circulation . 1999;  99 2908-2913
    CrossrefPubMedGoogle Scholar
  • 78 Marco J, Ariens R A, Fajadet J. Effect of aspirin and ticlopidine on plasma tissue factor levels in stable and unstable angina pectoris.  Am J Cardiol . 2000;  85 527-531
    CrossrefPubMedGoogle Scholar
  • 79 Kim H K, Song K S, Park Y S. Changes of plasma tissue factor and tissue factor pathway inhibitor antigen levels and induction of tissue factor expression on the monocytes in coronary artery disease.  Cardiology . 2000;  93 31-36
    CrossrefPubMedGoogle Scholar
  • 80 Nishiyama K, Ogawa H, Yasue H. Simultaneous elevation of the levels of circulating monocyte chemoattractant protein-1 and tissue factor in acute coronary syndromes.  Jpn Circ J . 1998;  62 710-712
    CrossrefPubMedGoogle Scholar
  • 81 Roldan V, Marin F, Fernandez P. Tissue factor/tissue factor pathway inhibitor system and long-term prognosis after acute myocardial infarction.  Int J Cardiol . 2001;  78 115-119
    CrossrefPubMedGoogle Scholar
  • 82 Kamikura Y, Wada H, Yamada A. Increased tissue factor pathway inhibitor in patients with acute myocardial infarction.  Am J Hematol . 1997;  55 183-187
    CrossrefPubMedGoogle Scholar
  • 83 Sandset P M, Sirnes P A, Abildgaard U. Factor VII and extrinsic pathway inhibitor in acute coronary disease.  Br J Haematol . 1989;  72 391-396
    PubMedGoogle Scholar
  • 84 Mallat Z, Benamer H, Hugel B. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes.  Circulation . 2000;  101 841-843
    CrossrefPubMedGoogle Scholar
  • 85 Gawaz M, Neumann F J, Ott I. Platelet function in acute myocardial infarction treated with direct angioplasty.  Circulation . 1996;  93 229-237
    CrossrefPubMedGoogle Scholar
  • 86 Dignat-George F, Blann A, Sampol J. Circulating endothelial cells in acute coronary syndromes.  Blood . 2000;  95 728
    PubMedGoogle Scholar
  • 87 Mesri M, Altieri D C. Endothelial cell activation by leukocyte microparticles.  J Immunol . 1998;  161 4382-4387
    PubMedGoogle Scholar
  • 88 Sabatier F, Roux V, Anfosso F. Interaction of endothelial microparticles with monocytic cells in vitro induces tissue factor-dependent procoagulant activity.  Blood . 2002;  99 3962-3970
    CrossrefPubMedGoogle Scholar
  • 89 Boulanger C M, Scoazec A, Ebrahimian T. Circulating microparticles from patients with myocardial infarction cause endothelial dysfunction.  Circulation . 2001;  104 2649-2652
    CrossrefPubMedGoogle Scholar
  • 90 Ott I, Malcouvier V, Schomig A. Proteolysis of tissue factor pathway inhibitor-1 by thrombolysis in acute myocardial infarction.  Circulation . 2002;  105 279-281
    CrossrefPubMedGoogle Scholar
  • 91 Stalboerger P G, Panetta C J, Simari R D. Plasmin proteolysis of endothelial cell and vessel wall associated tissue factor pathway inhibitor.  Thromb Haemost . 2001;  86 923-928
    PubMedGoogle Scholar
  • 92 Steppich B, Malcouvier V, Geith S. Proteolysis of tissue factor pathway inhibitor-1 after thrombolysis in acute myocardial infarction.  Eur Heart J . 2002;  23 262
    PubMedGoogle Scholar
  • 93 Petersen L C. Active site-inhibited seven: mechanism of action including signal transduction.  Semin Hematol . 2001;  38 39-42
    PubMedGoogle Scholar
  • 94 Houston D S. Tissue factor-a therapeutic target for thrombotic disorders.  Expert Opin Ther Targets . 2002;  6 159-174
    CrossrefPubMedGoogle Scholar
      >